Onyx Biotec IPO
- IPO Date13 Nov, 2024 to 18 Nov, 2024
- Listing Date21 Nov, 2024
- Face Value₹10 per share
- Issue Price₹58 to ₹61 per share
- Lot Size2000 Shares
- Minimum Investment₹1,22,000
- Listing AtNSE SME
- Total Issue Size48,10,000 Shares
(aggregating up to ₹29.34 Cr) - Fresh Issue48,10,000 Shares
(aggregating up to ₹29.34 Cr)
- Offer for Sale-
- Issue TypeBook Built Issue IPO
- Share holding pre issue1,33,22,200
- Shareholding post issue1,81,32,200
IPO Dates
Closing Date
18 Nov, 2024
Initiation of Refunds
20 Nov, 2024
Listing Date
21 Nov, 2024
13 Nov, 2024
Opening Date
19 Nov, 2024
Basis of Allotment
20 Nov, 2024
Credit of Shares
Onyx Biotec Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| S-HNI (Max) | - | - | - |
| Retail (Max) | 1 | 2000 | ₹1,22,000 |
| Retail (Min) | 1 | 2000 | ₹1,22,000 |
| B-HNI (Min) | - | - | - |
| S-HNI (Min) | 2 | 4000 | ₹2,44,000 |
Onyx Biotec Promoter Holding
| Pre Issue Share Holding | Post Issue Share Holding |
|---|---|
| 88.6% | - |
Onyx Biotec COMPANY INFORMATION
Onyx Biotec IPO is a book built issue of Rs 29.34 crores. The issue is entirely a fresh issue of 48.1 lakh shares. Onyx Biotec IPO opens for subscription on November 13, 2024 and closes on November 18, 2024. The allotment for the Onyx Biotec IPO is expected to be finalized on Tuesday, November 19, 2024. Onyx Biotec IPO will list on NSE SME with tentative listing date fixed as Thursday, November 21, 2024. Onyx Biotec IPO price band is set at ₹58 to ₹61 per share. The minimum lot size for an application is 2000 Shares. The minimum amount of investment required by retail investors is ₹122,000. The minimum lot size investment for HNI is 2 lots (4,000 shares) amounting to ₹244,000. Horizon Management Private Limited is the book running lead manager of the Onyx Biotec IPO, while Mas Services Limited is the registrar for the issue. The market maker for Onyx Biotec IPO is Giriraj Stock Broking. Refer to Onyx Biotec IPO RHP for detailed information.
Incorporated in May 2005, Onyx Biotec Limited is a pharmaceutical company providing sterile water for injections. The company currently manufactures Sterile Water for Injections and serves as a pharmaceutical contract manufacturer, offering a comprehensive range of Dry Powder Injections and Dry Syrups for both the Indian and overseas markets.
The company has two manufacturing units in Solan, Himachal Pradesh. Unit I has a daily production capacity of 638,889 units of Sterile Water for Injections, while Unit II produces 40,000 units of dry powder injections and 26,667 units of dry syrup per day in a single shift.
The company clientele includes Hetero Healthcare Limited, Mankind Pharma Limited, Sun Pharmaceutical Industries Limited, Aristo Pharmaceuticals Private Limited, Macleods Pharmaceuticals Limited, Mapra Laboratories Private Limited, Axa Parenterals Limited, FDC Limited, Zuventus Healthcare Limited, Akums Drugs and Pharmaceuticals Limited, Reliance Life Sciences Limited, among others.
As of May 31, 2024, the company had a client base of more than 100 Indian and multinational pharmaceutical companies.
The company has received certificates for the management system, ISO 9001:2015, and ISO 14001:2015 from ROHS Certification Private Limited.
As of July 31, 2024, the company has 175 employees across various departments.
Onyx Biotec IPO
IPO Overview and Key Highlights
Onyx Biotec is launching its Initial Public Offering (IPO), consisting of up to 48,10,000 equity shares at a face value of Rs 10 each. The IPO is a 100% fresh issue, with no Offer for Sale (OFS). Proceeds from the IPO will be utilized for business expansion, working capital requirements, and general corporate purposes. The equity shares will be listed on the NSE Emerge Platform.
Key IPO Details
- Type of Issue: Book Built Issue
- Total Issue Size: 48,10,000 equity shares
- Face Value: Rs 10 per share
- Offer Opens: November 13, 2024
- Offer Closes: November 18, 2024
- Listing Exchange: NSE Emerge Platform.
Company Overview
Onyx Biotec, incorporated in 2005, is engaged in biotechnology-based solutions and pharmaceutical development. The company focuses on innovation and caters to a wide array of industries, including healthcare, agriculture, and environment. Its operations are based in Himachal Pradesh, with a corporate office in Chandigarh. The promoters include experienced professionals such as Sanjay Jain and Harsh Mahajan, who have extensive expertise in the pharmaceutical and biotech sectors.
Financial Overview
The company has demonstrated consistent financial performance over the years. Proceeds from the IPO are expected to boost working capital and fund growth strategies, particularly for research and development initiatives.
Key Strengths of Onyx Biotec
- Innovation Focus: A strong emphasis on R&D positions the company well in the competitive biotech sector.
- Experienced Promoters: Leadership with proven expertise ensures strategic decision-making.
- Expanding Market: Increasing demand for biotech solutions supports potential revenue growth.
IPO Pros and Cons
Pros
- Sector Growth: The biotechnology sector is expanding rapidly, driven by rising demand for innovative healthcare solutions.
- Fresh Issue Proceeds: Funds raised will directly contribute to business expansion and operational improvements.
- Emerging Platform Visibility: Listing on NSE Emerge increases investor confidence and enhances visibility.
Cons
- Market Dependency: Reliance on specific sectors like healthcare may expose the company to economic fluctuations.
- Intense Competition: The biotech industry is highly competitive, requiring constant innovation to maintain relevance.
- First Public Issue: Uncertainty surrounding stock performance post-listing.
Risk Factors
Investors should consider the following risks:
- Regulatory Compliance: Biotechnology operations are subject to stringent regulations, which could impact costs and operations.
- Economic Sensitivity: Changes in the global or domestic economy may affect the demand for biotech solutions.
- Technology Risks: Staying competitive requires ongoing investments in technology and innovation.
Conclusion
The Onyx Biotec IPO offers a promising opportunity for investors seeking exposure to the growing biotech sector. With a strong focus on innovation and experienced leadership, the company is positioned for sustained growth. However, potential investors should carefully evaluate risks, including market dependency and regulatory challenges, before investing.
FAQs About Onyx Biotec Ipo
Onyx Biotec IPO will open on 13 Nov, 2024 and close on 18 Nov, 2024. Investors must apply within this period to participate.
The Onyx Biotec IPO price band is set between ₹58.00 and ₹61.00 per share. The minimum lot size is 2000, requiring an investment of at least ₹122000.00.
The Onyx Biotec IPO shares are expected to be listed on 21 Nov, 2024, subject to regulatory approvals and final allotment.
You can track your Onyx Biotec IPO application status on the registrar’s website: Link Intime or KFintech using your PAN, application number, or DP ID
The Onyx Biotec IPO will be listed on major stock exchanges such as BSE, where you can trade shares once they are listed.